Stay updated on Pembrolizumab in Neoplasms Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.

Latest updates to the Pembrolizumab in Neoplasms Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedSite version updated from v3.4.3 to v3.5.0. No visible changes to the study details, eligibility criteria, or other study content.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision: v3.4.3 now shown, replacing the previous v3.4.2.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedMinor metadata updates were made, including a revision tag (v3.4.2) and update dates (2026-02-10, 2026-01-29, 2026-01). The government funding lapse notice was removed.SummaryDifference0.6%

- Check50 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision to v3.4.1 (removing v3.4.0).SummaryDifference0.4%

- Check58 days agoChange DetectedGlossary display added; QC metadata updated to show Last Update Submitted that Met QC Criteria and Last Update Posted, with old QC labels replaced and Revision updated to v3.4.0.SummaryDifference0.3%

- Check72 days agoChange DetectedThe page's revision history shows an addition of 'Revision: v3.3.4' and a removal of 'Revision: v3.3.3'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Neoplasms Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.